# MRG003 With Gemcitabine for Second-line Advanced PDAC

> **NCT07685470** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Peking Union Medical College Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Pancreatic Ductal Adenocarcinoma (PDAC)
- Second Line Treatment

## Interventions

- **DRUG:** becotatugvedotin plus gemcitabine

## Key facts

- **NCT ID:** NCT07685470
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-08
- **Primary completion:** 2028-05-07
- **Final completion:** 2029-06-07
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07685470

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07685470, "MRG003 With Gemcitabine for Second-line Advanced PDAC". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07685470. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*